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A B S T R A C T
Endothelin-1 (ET-1) induces lipolysis in adipocytes, where ET-1 chronic exposure results in insulin
resistance (IR) through suppression of glucose transporter (GLUT)4 translocation to the plasma
membrane and consequently glucose uptake. ARF6 small GTPase, which plays a vital role in cell surface
receptors trafﬁcking, has previously been shown to regulate GLUT4 recycling and thereby insulin
signalling. ARF6 also plays a role in ET-1 promoted endothelial cell migration. However, ARF6
involvement in ET-1-induced lipolysis in adipocytes is unknown. Therefore, we investigated the role of
ARF6 in ET-1-induced lipolysis in 3T3-L1 adipocytes. This was achieved by studying the effect of
inhibitors for the activation of ARF6 and other signalling proteins on ET-1 induced lipolysis and ARF6
activation in the adipocytes. Our results indicate that ET-1 induces, through endothelin type A receptor
(ETAR), lipolysis, the ARF6 activation and extracellular-signal regulated kinase (ERK) phosphorylation in
adipocytes, further ET-1 stimulated lipolysis is inhibited by the inhibitors of ARF6 activation, ERK
phosphorylation and dynamin, which is essential for endocytosis. Our studies also revealed that ARF6
acts upstream of ERK in ET-1-indcued lipolysis. In summary, we determined that ET-1 activation of ETAR
signalled through ARF6, which is crucial for lipolysis.
 2014 Elsevier Inc. All rights reserved.
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An increase in lipolysis, which leads to triglyceride (TG)
breakdown and elevated plasma free fatty acids (FFAs), in
adipocytes contribute to insulin resistance (IR) through suppres-
sing insulin-stimulated glucose uptake [1]. The potent vasocon-
strictor hormone endothelin-1 (ET-1) signals through G-protein
coupled receptors (GPCRs) endothelin type A receptor (ETAR) and
endothelin type B receptor (ETBR) [2,3]. Through the activation of
ETAR, ET-1 can induce lipolysis in adipocytes [4]. ET-1 induces
lipolysis through the activation/phosphorylation of ERK1/2,
which then leads to the recruitment and activation of lipases
and regulatory proteins required for TG hydrolysis [4]. Chronic
ET-1 exposure impairs insulin-stimulated glucose uptake by
increasing lipolysis, causes IR by depleting phosphatidylinositol
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chain fatty acid (LCFA) uptake in adipocytes [5–7]. Plasma ET-1
concentrations are raised in obese, IR and type 2 diabetic (T2D)
patients [8,9]. The link between ET-1 and IR requires further
attention to combat obesity and T2D.
ADP-ribosylation factors (ARFs) are Ras-related guanosine
triphosphate (GTP)-binding proteins of about 21 kDa in size and
regulated through activation by guanine nucleotide-exchange
factors (GEFs) and inactivation by GTPase-activating proteins
(GAPs) [10]. They are major regulators of intracellular membrane
trafﬁcking. There are six mammalian ARF proteins (ARFs 1–6) and
among them ARF1 and ARF6 are the best characterised and least
related [11]. ET-1 has been shown to promote endothelial cell
migration through ARF6 activation [12]. ARF6 is also required for
internalisation of the GPCRs such as b2-adrenergic receptor (b2AR)
and Luteinizing hormone receptor (LHR) and isoproterenol-
stimulated lipolysis in adipocytes [13–16]. ARF6 has also been
associated with IR, where inactivation has been demonstrated to
suppress glucose-stimulated insulin secretion (GSIS) [17,18],
insulin signalling [19,20] and GLUT4 recycling to the plasma
membrane [21]. Stimulation of b2AR by isoproterenol leads to
activation of ARF6, protein kinase A (PKA) and perillipin on lipid
droplets, which allows enhanced substrate accessibility and
lipolysis by hormone sensitive lipase (HSL) [17]. Lipases such as
adipose triacylglycerol lipase (ATGL), TAG hydrolase and adiponu-
trin also participate in lipolysis, suggesting many pathways are
involved in the regulation of the lipid metabolism.
Dynamin GTPase regulates b2AR and LHR internalisation by
causing ﬁssion of clathrin coated vesicles [14,16,22]. It has been
shown that ARF6 regulates dynamin GTPase activity through
NM23-H1 during LHR internalisation [15]. The role of ARF6 in the
regulation of lipid metabolism through b2AR signalling was
established recently [16]. However it is unknown whether ARF6
participate in ET-1 induced lipid metabolism or not. To investigate
the role of ARF6 in ET-1 induced lipolysis in adipocytes, we utilised
glycerol release assays as read out for lipolysis. Chemical inhibitors
and membrane permeable inhibitory peptides for ARFs and other
signalling components were employed to analyse their effect on
lipolysis and ARF6 activation in ET-1 stimulated 3T3-L1 adipo-
cytes. Our study here demonstrate the activation of ARF6 in ET-1
stimulated adipocytes and the involvement of activated ARF6 in
ET-1 stimulated lipolysis in adipocytes through the ERK-phos-
phorylation and dynamin.
2. Materials and methods
2.1. Materials
Foetal calf serum (FCS), calf serum (CS) and Dulbecco’s modiﬁed
Eagle’s medium (DMEM) were from Biosera (Uckﬁeld, UK). 8-Br-
cAMP, BQ-123, dynasore, ET-1, PD98059, brefeldinA (BFA) and
secinH3 were from Abcam (Cambridge, UK). Penetratin, ARF1p-
penetratin and ARF6p-penetratin were synthesised by Thermo
Fisher Scientiﬁc (Cramlington, UK). LY294002 and QS11 were from
R&D Systems Europe Ltd. (Abingdon, UK). Dexamethasone,
forskolin, insulin, IBMX, rosiglitazone and free glycerol reagent
were from Sigma-Aldrich (Poole, UK). Mouse anti-Arf6 antibody
was from Santa Cruz biotechnology (Santa Cruz, CA). Anti-pERK1/2
and anti-total ERK1/2 antibodies were from New England Biolabs
(Hitchin, UK). All other chemical, unless otherwise speciﬁed, were
from Sigma-Aldrich (Poole, UK).
2.2. 3T3-L1 cell culture and differentiation
3T3-L1 preadipocytes were grown to conﬂuence in DMEM with
high glucose containing 10% CS and PSG (2 mM glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin). Two days after
reaching to conﬂuence, cells were induced to differentiate by
incubating them in the differentiation medium (0.5 mM IBMX,
0.25 mM dexamethasone, 10 mg/ml insulin, 2 mM rosiglitazone in
FSM [DMEM with high glucose containing 10% FCS and PSG]) for 2
days and then in FSM containing 10 mg/ml insulin for 2 days [23].
Cells were grown in FSM for 6 further days with FSM medium
replacing for every 2 days.
2.3. ARF6-GTP pulldown assay
ARF6 activation was assessed by using the GST-GGA3 protein
binding domain (PBD) pulldown assay as described previously
[14,24]. The GST-GGA3 PBD fusion protein was puriﬁed and
coupled to glutathione-sepharose beads (GE Healthcare, Little
Chalfont, UK) as described [25]. Differentiated adipocytes in a
10 cm plate were serum starved by washing twice with DMEM and
incubating in DMEM containing 0.5% fatty acid free bovine serum
albumin (BSA) for 16 h. The cells were then washed twice in ice-
cold phosphate-buffered saline (PBS) and lysed at 4 8C for 15 min
with 0.5 ml of ARF-GTP pulldown lysis buffer (25 mM Tris–HCl [pH
7.2], 150 mM NaCl, 5 mM MgCl2, 1% NP40, 5% glycerol) and 1%
protease inhibitors. The cell lysates were centrifuged at 14,000  g
for 10 min at 4 8C to pellet cellular debris. A 0.4 ml fraction of each
lysate was incubated with glutathione-beads coupled to 25 mg of
puriﬁed GST-GGA3 PBD fusion protein at 4 8C for 2 h. The beads
were washed three times with ARF-GTP pulldown wash buffer
(50 mM Tris–HCl, pH 7.5, 10 mM MgCl2, 150 mM NaCl and 1%
Triton X-100) and boiled in 50 ml 1 SDS-PAGE loading buffer for
5 min to release the bound protein into buffer. The lysates that
were not incubated with the beads (100 ml) were used to assess
total ARF6 and ERK1/2, and ERK1/2 phosphorylation. ARF6-GTP
bound to the beads and total ARF6, total ERK1/2 and ERK1/2-
phospho in the inputs were determined by SDS-PAGE and
immunoblotting using the anti-ARF6, anti-ERK1/2 and anti-
phospho ERK1/2 antibodies.
2.4. Immunoblotting
Proteins were separated by 12% SDS-PAGE, transferred onto
PVDF membrane and immunoblotted using appropriate primary
and HRP-conjugated secondary antibodies as described previously
[26].
2.5. Inhibition of ARF through penetratin-bound inhibitory peptides
The cell-permeating domain of Drosphila antennapedia protein
(penetratin), and the N-myristoylated ARF1 (ARF1p; consists of 2-
17 aa of ARF1) and ARF6 (ARF6p; consists of 2-13 aa of ARF6)
peptides fused to penetratin, to give the property of membrane
permeability, were used in this assay [14,27]. After serum
starvation for 16 h, differentiated 3T3-L1 adipocytes were pre-
incubated with 5 mM penetratin, ARF1p-penetratin or ARF6p-
penetratin for 30 min. ET-1 (10 nM) was then added and incubated
the cells for a further 4 h before glycerol content of the media was
quantiﬁed.
2.6. Glycerol release assay
Stimulation of adipocytes and measurement of glycerol release
were performed as described previously [28]. Before glycerol
release assay, adipocytes were serum-starved as described above
for 16 h. The cells were treated without or with chemical inhibitors
before lipolytic stimulation with ET-1 or other stimulants. Lipolysis
of triglycerides was quantiﬁed through the release of glycerol into
the culture medium using the free glycerol reagent [29].
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The statistical analysis software program GraphPad Prism was
used to determine signiﬁcance. The results are presented as
means  standard deviation (SD). Statistical signiﬁcance was
assessed by Student’s t-test or one-way ANOVA. A P value <0.05
was considered statistically signiﬁcant.
3. Results
3.1. ET-1 stimulates lipolysis in 3T3-L1 adipocytes
3T3-L1 adipocytes were incubated with 10 nM ET-1 for various
times and glycerol release was determined as the product of
lipolysis. As shown in Fig. 1A, a time dependent increase in lipolysis
was observed in cells treated with ET-1 when compared that in the
unstimulated control cells, with maximal lipolysis at 24 h of
stimulation (1053.9  40.3 vs 297.8  49.7 nmol/ml in unstimulated
cells, P < 0.001). 3T3-L1 adipocytes were then incubated for 4 h with
varying concentrations of ET-1 (0–1012 M) to study dose-dependent
effect of ET-1 on lipolysis. The lipolysis increase in a dose dependent
manner was observed (Fig. 1B). The maximal lipolysis seen with ET-1
at 106 M was six fold higher than that in the control unstimulated
cells (491.5  26.3 vs 74.8  5.3 nmol/ml, P < 0.001). Unless other-
wise indicated, a standard treatment protocol of 10 nM ET-1 for 4 h
was used in further experiments.
To conﬁrm ET-1 signals in adipocytes through ETAR [4], we
analysed the effect of ETAR antagonist BQ-123 on ET-1 stimulated
lipolysis in 3T3-L1 adipocytes. As shown in Fig. 1C, BQ-123 had no
effect on basal lipolysis. However, BQ-123 completely inhibited
ET-1 induced lipolysis, conﬁrming that ET-1 induced lipolysis is
mediated through ETAR. Since insulin has an anti-lipolytic effect on
adipocytes (7), we assessed whether it inhibit ET-1-induced
lipolysis (Fig. 1D). The presence of 10 nM insulin resulted inA
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Fig. 1. Endothelin-1 (ET-1) induces lipolysis in 3T3-L1 adipocytes through ETAR. Differe
absence (D) or presence (~) of ET-1 and measured the glycerol release (lipolysis). 3T3-
various concentrations (0.001 nM–1 mM) for 4 h (B). 3T3-L1 adipocytes were pre-incuba
(D), and then stimulated without or with 10 nM ET-1 for 4 h. Glycerol release was mea
**P < 0.01 and ***P < 0.001 compared with control.complete inhibition of ET-1 induced lipolysis. The glycerol released
in adipocytes treated with 10 nM ET-1 and 10 nM insulin was close
to that of basal.
3.2. ET-1 stimulation causes ARF6 and ERK1/2 activation in 3T3-L1
adipocytes
Active ARF6, the GTP-bound form, has been demonstrated to
participate in adrenergic stimulated lipolysis in 3T3-L1 adipocytes
[16]. The GST-GGA3 PBD speciﬁcally binds to the GTP-bound form
of ARF, and therefore it has been used in an assay for detecting the
ARF activation [14]. We used the GST-GGA3 PBD pulldown assay to
assess if ET-1 stimulation of 3T3-L1 adipocytes causes ARF6
activation. 3T3-L1 adipocytes were treated with 10 nM ET-1 for
various times and assessed the ARF6-GTP levels. As shown in
Fig. 2A, ARF6 was activated at 1 min and maintained activation
upto 1 h (5.4  1.3-fold over basal, P < 0.01). The time-dependent
assay revealed that the levels of ARF1-GTP were not increased in
adipocytes upon stimulation with ET-1 (data not shown), indicating
that ET-1 stimulation of 3T3-L1 adipocytes leads to the activation of
ARF6 only. ET-1 has also been shown to activate ERK1/2, through the
phosphorylation, in 3T3-L1 adipocytes [4]. The same time course
assay revealed that ERK1/2 is phosphorylated at 1 min and activation
peaked at 5 min (11.6  3.1-fold over basal, P < 0.001), before
returning to basal levels at 15 min (Fig. 2C).
Concentration-dependent activation of both ARF6 and ERK1/2
was assessed by incubating 3T3-L1 adipocytes with a variety of ET-
1 concentrations (0–106 M) for 5 min. As shown in Fig. 2B, ARF6
was activated at 1010 M, reaching the maximal activation at
108 M (6.4  0.1-fold over basal, P < 0.001). ERK1/2 was phosphor-
ylated at 1010 M, increasing phosphorylation levels to maximal at
106 M (6.3  1.2-fold over basal, P < 0.01) (Fig. 2D). These data
demonstrate ET-1 induced activation of both ARF6 and ERK1/2 in a
concentration-dependent manner. In ET-1 treated cells, ARF6 isD
0
50
100
150
200
250
300
350
400
450
ET-1 (10nM)     -             +              -             +
Insuli n (10 nM )   -              -             +             +
***
##
G
ly
ce
ro
l R
el
ea
se
(n
m
ol
/m
l)
B
- -12 -11 -10 -9 -8 -7 -6
0
100
200
300
400
500 *********
***
***
***
***
ET-1 (log  M)
G
ly
ce
ro
l R
el
ea
se
(n
m
ol
/m
l)
ntiated 3T3-L1 adipocytes were serum starved for 16 h and then incubated in the
L1 adipocytes were stimulated with 10 nM ET-1 for various times (0.5–24 h) (A) or
ted for 1 h without or with 10 nM BQ-123 (an ETAR antagonist) (C) or 10 nM insulin
sured and the results displayed as means  SD of 3 separate experiments. *P < 0.05,
Fig. 2. ARF6 and ERK1/2 are activated in 3T3-L1 adipocytes by ET-1 stimulation. Differentiated 3T3-L1 adipocytes were serum starved and treated with ET-1 for various times
(10 nM for 0–60 min) (A and C) or at varying concentrations (0.1–1 mM) for 5 min (B and D). The cells were then lysed and the cell lysates were incubated with GST-GGA3 PBD
resin. The protein bound to the resin was analysed by immunoblot using an anti-ARF6 antibody to analyse the levels of ARF6-GTP. The cell lystes that not incubated with the
GST-beads were also immunoblotted with an anti-ARF6 antibody, an anti-ERK antibody and an anti-ERK-phospho speciﬁc antibody for analysing total ARF6, total ERK1/2 and
the phosphorylated ERK1/2 (ERK1/2-p). Blot images are representative of three separate experiments. Densitometric analysis of ARF6-GTP (A and B, lower panel) and ERK 1/2-
p (C and D, lower panel) is shown as a histogram, after normalizing to the expression of total ARF6 and total ERK1/2, respectively, present in the sample. *P < 0.05, **P < 0.01
and ***P < 0.001 compared with control.
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2 is activated and peaked within 5 min.
3.3. ET-1 induced lipolysis is mediated by ARF6, ERK and dynamin
PreviousstudiessuggestedtheinvolvementofARF6,dynaminand
ERK signalling proteins in agonist-induced lipolysis in differentiated
3T3-L1 adipocytes [4,16]. To analyse the role of ARF6, ERK1/2 and
dynamin in ET-1 induced lipolysis, we made use of the chemical
inhibitors speciﬁc for these signalling proteins. We ﬁrst assessed the
role of ARF6 in ET-1 induced lipolysis by using membrane permeable
ARF6p-penetratin and ARF1p-penetratin peptides, which have
been shown to inhibit ARF6 and ARF1 functions, respectively [30].
3T3-L1 adipocytes were pre-treated with 5 mM penetratin (control),
ARF1p-penetratin or ARF6p-penetratin, then stimulated cells with
10 nM ET-1 and measured the glycerol release. As shown in Fig. 3A,
treatment of 3T3-L1 adipocytes with ARF6p-penetratin, but not
ARF1p-penetratin, inhibited ET-1 induced lipolysis (294.4  78.4 vs
420.7  36.6 nmol/ml in control treated with no peptide, P < 0.01).
This indicated that ARF6 is essential for the lipolysis induced by
ET-1.
ARF6 is active in the GTP-bound form and inactive in the GDP-
bound form. ARF6 is activated by GEFs whereas it is inactivated by
GAPs. ARF6 activation can be inhibited with secinH3, an inhibitor
of the cytohesin family of ARF GEFs but not with BFA, an ARF GEF
inhibitor speciﬁc for the other ARFs activation [14]. Cells were
stimulated with 10 nM ET-1 in the presence of different
concentrations (0–100 mM) of secinH3 and measured the glycerol
release. As shown in Fig. 3B, secinH3 inhibited ET-1 induced
lipolysis by 2.2 fold at 6.25 mM concentration. The glycerol content
released from adipocytes treated with 10 nM ET-1 and 6.25 mMsecinH3 was lower when compared with that released by 10 nM
ET-1 alone treated cells (387.9  59.4 vs 536.7  98.8 nmol/ml,
P < 0.001), the maximal inhibition of ET-1 induced lipolysis was
observed in the presence of 100 mM secinH3 (204.9  26.8 nmol/ml,
P < 0.001). Conversely, QS11, an inhibitor of ARF GAP, slightly
increased glycerol release from 3T3-L1 adipocytes stimulated with
10 nM ET-1 in a dose dependent manner (Fig. 3C), reaching maximal
lipolysis at 100 mM QS11 (575.0  18.21 vs 492.4  10.05 nmol/ml,
P < 0.001). However, the ARF GEF inhibitor BFA had no effect on ET-1
induced lipolysis (373.1  38.45 nmol/ml vs 382.5  15.32 nmol/ml
in control, P < 0.001 [Fig. 3D]). Previous studies indicated that agonist
(ET-1, EGF, hCG etc.) activation of ARF6 is mediated by PI3K
[12,14,31], which is inhibitable by compounds such as LY290004.
As shown in Fig. 3D, inhibition of P13K with LY294002 signiﬁcantly
reduced the lipolysis stimulated by ET-1 (160.8  17.68 vs
382.5  15.32 nmol/ml in control, P < 0.001).
Next, cells were preincubated with different concentrations (0–
100 mM) of the MEK-1 inhibitor, PD98059, for 1 h and measured
10 nM ET-1 stimulated glycerol release. As shown in Fig. 3E, the
glycerol released from adipocytes stimulated with 10 nM ET-1 in
the presence of 6.25 mM PD98059 was lower than that released by
stimulation of the cells with ET-1 alone (457.8  31.9 vs
597.8  58.7 nmol/ml, P < 0.01), the maximal inhibition of ET-1
induced lipolysis was observed in presence of 50 mM PD98059
(353.3  38.4 nmol/ml, P < 0.001). In presence of 6.25 mM PD98059,
there was a 1.5 fold inhibition of ET-1 induced lipolysis.
The role of dynamin in ET-1 induced lipolysis was assessed by
measuring 10 nM ET-1 stimulated glycerol from 3T3-L1 adipocytes
in the presence of different concentrations (0–100 mM) of
dynasore, a dynamin chemical inhibitor. As shown in Fig. 3F, the
lipolysis in adipocytes treated with 10 nM ET-1 and 6.25 mM
Figure 3
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Fig. 3. ET-1 induced lipolysis involves ARF6, ERK1/2 and dynamin. Differentiated 3T3-L1 adipocytes serum starved for 16 h were pre-incubated in the absence or presence of
penetratin or penetratin conjugated ARF1p or ARF6p for 30 min (A), SecinH3 (B) or QS11 (C) for 2 h [14], and LY294002 or BFA (D), PD98059 (E) or Dynasore (F) for 1 h. The
cells were stimulated without or with ET-1 (10 nM) for 4 h and measured glycerol concentration in the medium. The results are means  SD of triplicate measurements and are
representative of those for 3 separate experiments. ***P < 0.001 compared with control and ##P < 0.01, ###P < 0.001 compared with ET-1 alone.
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treated cells (293.7  43.7 vs 473.6  73.9 nmol/ml, P < 0.01),
where maximal inhibition was observed at 100 mM
(144.0  47.2 nmol/ml, P < 0.001). In the presence of 6.25 mM
dynasore, there was a 2.6 fold inhibition of ET-1 induced lipolysis.
3.4. ARF6 acts upstream of ERK1/2 in ET-1 induced lipolysis
The activation of both AFR6 and ERK 1/2 was then assessed in
ET-1 stimulated 3T3-adipocytes. Chemical inhibitors were again
utilised to determine the sequence of the signalling pathway
following ETAR activation. 3T3-L1 adipocytes were pre-incubated
with secinH3 (50 mM) for 2 h, PD 98059, dynasore, BFA and
LY429002 (50 mM) for 1 h. Cells were then stimulated with ET-1
(10 nM) for 5 min before lysing and subjecting to the GST GGA3
PBD pulldown assay. As shown in Fig. 4, secinH3, but not BFA,
prevented the activation of ARF6 in ET-1 stimulated adipocytes
(1.1  0.2-fold vs 6.0  0.6-fold, P < 0.001), and also ERK1/2
(1.4  0.3-fold vs 6.4  1.4-fold, P < 0.01). ERK1/2 phosphorylation
was also prevented through treatment with PD98059 (1.3  0.2-fold
vs ET-1 alone, P < 0.01), but the MEK-1 inhibitor did not prevent ARF
activation (6.0  1.0-fold vs ET-1 alone). These observations imply
that ARF6 could be upstream to ERK1/2 in ET-1 induced lipolysis
signalling. Inhibition of PI3K also prevented the activation of ARF6
and ERK1/2, which is consistent with our previous observation thatPI3K activates ARF6 in growth factor stimulated cells [31]. This would
imply a role for PI3K in ET-1 induced lipolysis, acting upstream of
ARF6 and ERK1/2. Inhibition of dynamin had no effect on either ARF6
or ERK1/2 activation.
3.5. Inhibition of ARF6 activation does not affect lipolysis induced by
8-Br-cAMP, IBMX or forskolin
We ﬁnally studied whether ARF6 play a role in ET-1-induced
lipolysis by regulating ETAR downstream signalling pathway. For
this purpose, the effect of inhibition of ARF6 activation on lipolysis
stimulated by directly activating the signalling pathway down-
stream of ETAR was assessed. ETAR is a GS coupled GPCR and
therefore it stimulates cAMP production upon activation. A cell-
membrane permeable cAMP analogue 8-Br-cAMP (1 mM), the
phosphodiesterase (PDE) inhibitor IBMX (0.5 mM) and the
adenylyl cyclase activator forskolin (10 mM), which stimulate
cAMP production independent of ETAR activation, were used to
induce lipolysis [4]. 3T3-L1 adipocytes were treated with 8-Br-
cAMP, IBMX and forskolin separately in the presence or absence of
secinH3 (50 mM) and glycerol content was quantiﬁed As shown in
Fig. 5, the lipolysis induced by these three chemicals is not affected
by ARF6 inactivation by secinH3, indicating that ARF6 regulates ET-
1 induced lipolysis not through ETAR downstream Gs-coupled
signalling pathway.
Fig. 4. ARF6 acts upstream of ERK 1/2 in ET-1 induced lipolysis. 3T3-L1 adipocytes were serum starved for 16 h and preincubated with SecinH3 (50 mM) for 2 h [14], and
PD98059 (50 mM), Dynasore (50 mM), BFA (50 mM) or LY294002 (50 mM) for 1 h. Cells were then stimulated with ET-1 for 5 min. ARF6-GTP and ERK1/2-p in adipocytes
neither pre-incubated nor stimulated with ET-1 were considered as basal activities. The cells were then lysed and a fraction of the cell lysate was incubated with GST-GGA3
PBD resin to analyse the levels of ARF6-GTP. The remaining cell lysate was used for analysis of total ARF, total ERK1/2 and the phosphorylated ERK1/2 (ERK1/2-p). (A) Total and
the activated ARF6 (ARF6-GTP) were analysed by immunoblotting using an anti-ARF6 monoclonal antibody. (B) Total and ERK1/2-p were analysed by immunoblotting using
an anti-ERK1/2 polyclonal antibody and an anti-ERK1/2-phospho polyclonal antibody, respectively. Blot images are representative of three separate experiments.
Densitometric analysis of ARF6-GTP (A, lower panel) and ERK1/2-p (B, lower panel) is shown as a histogram after normalizing to the expression of total ARF6 and total ERK1/2,
respectively, present in the sample. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with control. ##P < 0.01 and ###P < 0.001 compared with ET-1 alone.
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This study was performed to investigate the role of ARF6 in ET-1
induced lipolysis of 3T3-L1 adipocytes and to determine the
signalling pathways of this process. We have demonstrated the
following in this study. First, ETAR antagonist and insulin inhibit
ET-1 induced lipolysis. Second, ARF6 and ERK1/2 activate upon ET-
1 stimulation in 3T3-L1 adipocytes. Third, chemical inhibition of
both ARF6 and ERK1/2 result in decreased ET-1 induced lipolysis.
Fourth, ARF6 activation precedes the ERK1/2 activation in ET-1
signalling. Fifth, inactivation of dynamin inhibits ET-1 induced
lipolysis and signals through different pathways to that of ARF6/
ERK1/2. Sixth, chemical inhibition of ARF6 does not affect lipolysis
induced by activators (8-Br-cAMP, IBMX and forskolin) of the
pathway downstream of ETAR. Collectively, these data demon-
strate that ARF6 is required for ET-1 induced lipolysis in
adipocytes.
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Fig. 5. Inhibition of ARF6 activation does not affect lipolysis stimulated by 8-bromo-
cAMP, IBMX or forskolin. 3T3-L1 adipocytes were serum starved for 16 h, pre-
incubated for 2 h in the absence or presence of 50 mM secinH3 [14] and then treated
with 8-bromo-cAMP, IBMX or forskolin. Glycerol concentration in the medium was
measured. The results are means  SD of triplicate measurements and are
representative of those for 3 separate experiments (***P < 0.001 compared with none).inhibitors (secinH3 and BFA) in our study revealed that ARF6, but
not ARF1, was essential for ET-1 stimulated lipolysis. By using
these peptides previously and chemical inhibitors, ARF6 has been
demonstrated to participate in LHR receptor internalisation [14].
Furthermore, ARF6 has been shown to be required for isoprotere-
nol induced lipolysis [16] and ERK1/2 phosphorylation is involved
in lipolysis stimulated by ET-1 [4]. Furthermore, secinH3, an
inhibitor of ARF6 activation, treatment of adipocytes in this study
lead to a signiﬁcant decrease in ET-1 induced lipolysis and ERK1/2
phsophorylation. However PD98059, an ERK inhibitor, treatment
of adipocytes reduced ET-1 stimulated lipolysis but had no effect
on ET-1 stimulated ARF6 activation, indicating that ARF6 regulates
ET-1 induced lipolysis through ERK1/2 phosphorylation. ET-1
stimulation of 3T3-L1 adipocytes led to increased lipolysis,
transient ERK1/2 phosphorylation and sustained ARF6 activation.
A previous study also reported transient phosphorylation of ERK1/
2 in ET-1 stimulated preadipocytes [4]. Although exactly how
transiently phosphorylated ERK1/2 regulate sustained lipolysis is
unknown, it is possible that the phosphorylated ERK1/2 may be
required only to initiate or recruit the signalling cascade that leads
to lipolysis. In contrast, ARF6 may activate not only ERK1/2 but also
several components within the signalling cascade and additional
signalling components (for example dynamin) involved in lipolysis
and therefore its sustained activation allow sustained lipolysis.
The involvement of dynamin in ET-1 stimulated lipolysis was
also established in this study by using a dyamin chemical inhibitor
dynasore, which inhibited ET-1 induced lipolysis but not the ARF6
activation or ERK1/2 phosphorylation. Dynamin is involved in cell
surface receptor internalisation, in which its function is to regulate
vesicle budding from coated pits [16]. It has been shown previously
that dynamin is required for b2AR and LHR internalisation [14,22].
Dynamin also known to function down stream of ERK during
preadiopocyte migration [32]. If dynamin participates in ET-1
induced lipolysis by regulating ETAR internalisation, then its
inhibition should effect not only ET-1 induced lipolysis but also the
activity of ARF6 and ERK1/2, which function downstream of ETAR.
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Fig. 6. Schematic model representing the role of ARF6 in ET-1 induced lipolysis. Binding of ET-1 to the receptor initiates signalling through the ARF6 activation, which
subsequently activates ERK1/2 and probably dynamin. The activated ERK1/2 and dynamin affect lipolysis, leading to hydrolysis of triglyceride (TG) to free fatty acids (FFAs)
and glycerol.
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lipolysis but had no effect on either ARF6 activation or ERK1/2
phosphorylation, it is possible that dynamin functions down
stream of ERK in ET-1 induced lipolysis.
To determine the sequence of signalling following ET-1
stimulation that leads to lipolysis, chemical inhibitors of various
signalling molecules were utilised. SecinH3, which affect ARF6
activation by inhibiting the cytohesin family of ARF GEFs,
treatment resulted in inhibition of both ARF6 and ERK1/2
activation. Through the use of the MEK-1 inhibitor, ERK1/2
activation was understood to act downstream of ARF6 activation,
which was unaffected by ERK1/2 inhibition. We have shown
previously that ARF6 is activated through PI3K [14,31]. This is
because the cytohesin family of ARF GEFs translocate from the
cytosol to the plasma membrane in a PI3K-dependent manner,
where they activate ARF6 [33,34]. Inhibition of PI3K by LY294002
treatment, prevented ARF6 and ERK1/2 activation in ET-1
stimulated cells. This is consistent with the role of PI3K in
ARF6 activation. Ligand binding to GPCR initiates subsequent
signalling, which is terminated by receptor internalisation and
desensitisation [35]. Chronic ET-1 exposure induces IR through
PIP2 depletion but suppresses LCFA uptake independent of the
PIP2 levels [7]. However, the inhibition of ERK activation prevents
ET-1 suppression of LCFA uptake, indicating that ET-1 suppresses
LCFA through the ERK dependent pathway [7]. In conclusion, the
ﬁndings here suggest ET-1 activation of ETAR leads to activation of
ARF6, which subsequently activates ERK1/2. The activated ERK1/2
then inhibits LCFA uptake and induces signalling upstream to TG
hydrolysis. As shown in this study, dynamin inhibition with
chemical inhibitor dynasore affected the ET-1 induced lipolysis.
However, dynasore had no effect on the activation of ARF6 or
ERK1/2 in ET-1 stimulated cells. Previous studies indicate that
dynamin functions downstream of ARF6 and ERK [14,20,32].
There it is possible that dynamin is involved downstream ARF6 in
ET-1 induced lipolysis.
Considering the results described in this study, we proposed a
model including ARF6 activation and subsequent ERK1/2 activa-
tion within the ET-1 lipolysis pathway (Fig. 6). Following the
activation of ETAR by ET-1, cytohesins recruits to the plasma
membrane in a PI3K dependent manner and activate ARF6, whichin turn activates ERK1/2 through phosphorylation. The activated
ERK1/2 then phosphorylates lipid droplet associated proteins and
lipases, leading to dynamic changes in those proteins location and
activity required for the TG hydrolysis [4]. In conclusion, the
present study demonstrates the necessity of ARF6, dynamin and
ERK1/2 activation within the ET-1 induced lipolysis. Future studies
on the involvement of ARF6/ERK in regulation of lipid droplet
associated proteins required for ET-1 induced lipolysis would
allow further knowledge of the role of ARF6 in lipid metabolism
and the close link between development of obesity, insulin
resistance and T2DM.
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